Fremanezumab is a humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
- Mechanism
- Curator reviewed · 3 references
Studies dating back to 1985 have demonstrated that CGRP levels increase during acute migraine attacks in migraine-suffering patients but normalize after administration of antimigraine therapy such as sumatriptan. Moreover, research has shown that intravenous administration of CGRP can induce migraine-like attacks in migraine-suffering patients. For these reasons, and despite the fact that their role in migraine headaches has not been entirely elucidated, CGRP and its receptors have become desirable targets for antimigraine therapies. Fremanezumab is a humanized monoclonal antibody directed against endogenous CGRP - it interferes with the activity of CGRP, preventing its downstream effects and ultimately mitigating the development of migraine headaches.
- Primary indication
- Fremanezumab is indicated for the preventative treatment of migraine in adults.Curator reviewed · 2 structured indications
- Formula / weight
- 148000.0 Da
- First approval
- Canada, 2020 · United States, 2018 · European Union, 2020
- Also known as
- Fremanezumab-Vfrm
- Code names
- TEV-48125
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Fremanezumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account